Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Nov;34(11):2223–2227. doi: 10.1128/aac.34.11.2223

In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum.

A G Arguedas 1, J C Akaniro 1, H R Stutman 1, M I Marks 1
PMCID: PMC172026  PMID: 2073112

Abstract

By using broth microdilution methods, the in vitro activity of tosufloxacin (A-64730), a new quinolone, was compared with those of other agents, including five quinolones, against geographically diverse cystic fibrosis sputum isolates obtained from 26 cystic fibrosis centers in the United States. These included Pseudomonas aeruginosa, conventional as well as especially resistant (ceftazidime, aztreonam, gentamicin, and/or tobramycin) isolates: Escherichia coli; Pseudomonas cepacia; Staphylococcus aureus; and Haemophilus influenzae. Tosufloxacin MICs for 50 and 90% of isolates of standard P. aeruginosa were 0.5 and 2.0 mg/liter, for resistant P. aeruginosa they were 4.0 and greater than 16.0 mg/liter, for E. coli they were less than or equal to 0.016 mg/liter, for P. cepacia they were 4.0 and 8.0 mg/liter, for S. aureus they were 0.063 and 0.063 mg/liter, and for H. influenzae they were less than or equal to 0.016 and 0.032 mg/liter, respectively. Tosufloxacin activities against standard and resistant strains of P. aeruginosa were similar to those of comparative quinolones. Against E. coli, tosufloxacin activity was similar to those of other quinolones. Against S. aureus, tosufloxacin activity was similar to those of trimethoprim-sulfamethoxazole and cephalexin, but tosufloxacin was more active than other agents. Against H. influenzae, tosufloxacin activity was similar to those of other quinolones. There was minor diminution of activity at pH 8.2 but major diminution of activity at pH 5.2 and at inoculum sizes of greater than or equal to 10(7) CFU/ml. Activity was unaffected by sputum but was enhanced by serum and by the omission of cation supplementation. Tosufloxacin has consistent activity against common cystic fibrosis pathogens. Its high degree of activity against S. aureus with activity maintained against P. aeruginosa and other gram-negative bacteria of interest suggests that further in vitro studies and assessment of activity in in vivo models of cystic fibrosis pulmonary infections are warranted.

Full text

PDF
2223

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blaser J., Lüthy R. Comparative study on antagonistic effects of low pH and cation supplementation on in-vitro activity of quinolones and aminoglycosides against Pseudomonas aeruginosa. J Antimicrob Chemother. 1988 Jul;22(1):15–22. doi: 10.1093/jac/22.1.15. [DOI] [PubMed] [Google Scholar]
  2. Borobio M. V., Perea E. J. Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria. Antimicrob Agents Chemother. 1984 Mar;25(3):342–343. doi: 10.1128/aac.25.3.342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chin N. X., Neu H. C. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984 Mar;25(3):319–326. doi: 10.1128/aac.25.3.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Daikos G. L., Lolans V. T., Jackson G. G. Alterations in outer membrane proteins of Pseudomonas aeruginosa associated with selective resistance to quinolones. Antimicrob Agents Chemother. 1988 May;32(5):785–787. doi: 10.1128/aac.32.5.785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dobbs B. R., Gazeley L. R., Stewart I. A., Edwards I. R. Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days. J Antimicrob Chemother. 1988 Feb;21 (Suppl B):61–66. doi: 10.1093/jac/21.suppl_b.61. [DOI] [PubMed] [Google Scholar]
  6. Eliopoulos G. M., Gardella A., Moellering R. C., Jr In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother. 1984 Mar;25(3):331–335. doi: 10.1128/aac.25.3.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Espinoza A. M., Chin N. X., Novelli A., Neu H. C. Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob Agents Chemother. 1988 May;32(5):663–670. doi: 10.1128/aac.32.5.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fernandes P. B., Chu D. T., Swanson R. N., Ramer N. R., Hanson C. W., Bower R. R., Stamm J. M., Hardy D. J. A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1988 Jan;32(1):27–32. doi: 10.1128/aac.32.1.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fujimaki K., Noumi T., Saikawa I., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother. 1988 Jun;32(6):827–833. doi: 10.1128/aac.32.6.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Govan J. R. Mucoid strains of Pseudomonas aeruginosa: the influence of culture medium on the stability of mucus production. J Med Microbiol. 1975 Nov;8(4):513–522. doi: 10.1099/00222615-8-4-513. [DOI] [PubMed] [Google Scholar]
  11. Jorgensen J. H., Redding J. S., Maher L. A., Howell A. W. Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol. 1987 Nov;25(11):2105–2113. doi: 10.1128/jcm.25.11.2105-2113.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Krieg D. P., Bass J. A., Mattingly S. J. Aeration selects for mucoid phenotype of Pseudomonas aeruginosa. J Clin Microbiol. 1986 Dec;24(6):986–990. doi: 10.1128/jcm.24.6.986-990.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. LeBel M., Bergeron M. G., Vallée F., Fiset C., Chassé G., Bigonesse P., Rivard G. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother. 1986 Aug;30(2):260–266. doi: 10.1128/aac.30.2.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sanders C. C., Sanders W. E., Jr, Goering R. V., Werner V. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother. 1984 Dec;26(6):797–801. doi: 10.1128/aac.26.6.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Stutman H. R., Shalit I., Marks M. I., Greenwood R., Chartrand S. A., Hilman B. C. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. Am J Med. 1987 Apr 27;82(4A):142–145. [PubMed] [Google Scholar]
  16. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES